Ricerca Biosciences Releases Foresight Similarity Analysis Service
Ricerca Biosciences
, a preclinical contract research organization providing services to the biopharmaceutical industry, has announced its similarity analysis service, Foresight™.
Foresight allows compound assay results to be compared against the assay results of a large reference set of pharmacologically active compounds. The tool helps predict
in vivo
effects from
in vitro
pharmacology data and provides insight into additional, non-obvious compound activities.
The analysis service allows scientists to discover clues to the possibilities of a compound. Foresight can be used to direct compound modification to avoid adverse effects and determine new indications for safe or novel compounds.
Ricerca has previous worked with clients to profile compounds in the discovery space. With the development of this tool, Ricerca can now offer interpretation and predictive analysis of pharmacological data.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
